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Functional characterisation of a 
novel class of in-frame insertion 
variants of KRAS and HRAS
Astrid eijkelenboom1, Frederik M. A. van schaik2, Robert M. van es2, Roel W. ten Broek1, 
tuula Rinne  3, Carine van der Vleuten4, Uta Flucke1, Marjolijn J. L. Ligtenberg1,3 & 
Holger Rehmann2,5
Mutations in the RAS genes are identified in a variety of clinical settings, ranging from somatic 
mutations in oncology to germline mutations in developmental disorders, also known as ‘RASopathies’, 
and vascular malformations/overgrowth syndromes. Generally single amino acid substitutions are 
identified, that result in an increase of the GTP bound fraction of the RAS proteins causing constitutive 
signalling. Here, a series of 7 in-frame insertions and duplications in HRAS (n = 5) and KRAS (n = 2) is 
presented, resulting in the insertion of 7–10 amino acids residues in the switch II region. These variants 
were identified in routine diagnostic screening of 299 samples for somatic mutations in vascular 
malformations/overgrowth syndromes (n = 6) and in germline analyses for RASopathies (n = 1). 
Biophysical characterization shows the inability of Guanine Nucleotide Exchange Factors to induce GTP 
loading and reduced intrinsic and GAP-stimulated GTP hydrolysis. As a consequence of these opposing 
effects, increased RAS signalling is detected in a cellular model system. Therefore these in-frame 
insertions represent a new class of weakly activating clinically relevant RAS variants.
Overgrowth syndromes, including vascular malformations represent a spectrum of conditions with congenital, 
aberrant vascular structures combined with overgrowth of surrounding tissue1–4. The identification and classi-
fication of vascular malformations/overgrowth syndromes, hereafter referred to as VMOS, can be challenging 
for physicians, pathologists and clinical geneticists. Usually the combination of clinical course and radiological 
investigations leads to a diagnosis as defined within the ISSVA classification1. VMOS do not display deviant vas-
cular histology in all cases. Histopathological investigation may be indicated to rule out a (vascular) tumour and 
in particular malignancy.
Vascular malformations may consist of either aberrant capillary, lymphatic, venous or arteriovenous vessels or 
a combination of those. Depending on the vessel-type, the patient may experience swelling, congestion, disfigure-
ment, (disabling) pain, thrombosis, embolism or bleeding. Although vascular malformations are usually benign 
conditions, all symptoms mentioned may result in significant complications and morbidity.
This spectrum of lesions is caused by somatic de novo mutations that occur during embryonal development 
resulting in mosaicism or rarely by germline mutations. Depending on the event and location of the mutation, the 
clinical presentation caused by somatic mutations can resemble those of patients affected by germline mutations. 
Generally, activating mutations are identified in genes associated with cell proliferation, cell growth, cell cycle 
regulation, and survival, while inactivating mutations are identified in genes with opposite biological functions5–8. 
Genetic tools for vascular anomalies have broadened the diagnostic scope. Sensitive Next Generation Sequencing 
(NGS) based approaches can be used to screen for mosaicism, which aids in diagnosis, exclusion of germline 
causes and allows identification of potentially clinically targetable disruptions9.
Germline and somatic mutations in genes coding for proteins of the RAS/MAPK pathway are known to cause 
a spectrum of congenital diseases named ‘RASopathies’ including Neurofibromatosis type I, Noonan syndrome, 
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and capillary malformation-arteriovenous malformation syndrome10. In a subset of cases of VMOS, somatic 
pathogenic mutations in genes associated with RAS signalling are identified, including mutations that causes 
enhanced signalling in the RAS genes themselves9,11,12. RAS mediated signalling is well studied, as somatic muta-
tions in KRAS are found commonly in tumours whereas mutations in HRAS and NRAS are found with much 
lower frequency. Oncogenic variants are typically found at hotspots in the RAS genes causing substitutions of 
residues Gly12, Gly13, Gln61, Lys117 or Ala146 and are referred to here as ‘classical mutations’.
HRAS, KRAS and NRAS are small G-proteins with high sequence homology. Small G-proteins cycle between a 
GDP and a GTP bound state, whereby the GTP bound state causes downstream signalling13,14. Under physiological 
conditions, the net transition to the GTP bound state occurs by nucleotide exchange as a dissociated nucleotide is 
replaced with higher probability by GTP than GDP due to the high cellular concentration of GTP. Nucleotide release 
is accelerated by Guanine Nucleotide Exchange Factors (GEFs). GEFs induce RAS signalling. Hydrolysis of GTP to 
GDP and phosphate by the G-protein results in the transition to the GDP bound state. The low intrinsic GTPase activ-
ity of small G-proteins is accelerated by several orders of magnitude by GTPase Activating Proteins (GAPs). Thereby 
GAPs terminate RAS signalling. The conformation of the G-protein, in particular of the so-called switch I and switch 
II region, depends on the nature of the bound nucleotide. Effector proteins interact selectively with the GTP-bound 
conformation. An increase of the GTP bound fraction of the G-protein thus enhances downstream RAS signalling. 
Mutations causing such a shift are therefore referred to as activating.
The molecular effects that result in an increase of the GTP bound fraction differ. Gly12 is localised in the 
P-loop that is involved in binding of the phosphate moiety of the nucleotide15. Missense mutations of Gly12 
reduce the rate of intrinsic GTP hydrolysis and the catalytic effect of GAPs. To catalyse GTP hydrolysis, GAPs for 
RAS proteins provide an arginine residue, the positive charge of which compensates for the negative charge that 
accumulates at the γ-phosphate during hydrolysis upon the nucleophilic attack by a water molecule. Missense 
mutations of Gly12 sterically prevent the proper positioning of this arginine residue16. The same effect occurs 
if Gly13 is mutated. The side chain of Gln61 positions the attacking water molecule by a direct hydrogen bond 
and is itself stabilised in a catalytic competent conformation by RasGAP15–17. Hydrolysis is less efficient without 
proper positioning of the attacking water and in addition mutations of Gln61 reduce the affinity to RasGAP. 
Lys117 is part of the NKxD motif and Ala146 of the SAK motif. Both motifs are involved in binding the base 
of the nucleotide17. Alterations in this motif result in decreased nucleotide affinity and thus increase nucleotide 
dissociation rates. As a consequence, intrinsic nucleotide exchange is increased and thereby the fraction of GTP 
bound RAS.
Here, a series of 7 novel in-frame insertions in HRAS and KRAS, identified in routine diagnostic screening 
for somatic mutations in VMOS and germline screening for RASopathies, are functionally characterised. These 
variants display unique properties and act as weakly but constitutively activating.
Results
patient cohort. NGS based analysis was performed routinely in cases where VMOS were diagnosed based 
on clinical, radiological, and histopathological evaluation. These were cases in which initially no clear diagnosis 
of VMOS was possible or where treatment was insufficient with progression of the lesion. In this respect the cases 
were classified as “atypical” VMOS. In cases of smaller lesions surgical excision and otherwise incision biopsy was 
performed. Histopathological investigation could exclude malignancy.
Identification of RAS in-frame insertions. Sensitive NGS based screening of frequently mutated positions in 
a panel of multiple genes were applied in 299 cases. In 108 cases, putative causative variants were identified, of which 
in 15 cases RAS genes were affected (Fig. 1A). 7 of the 15 variants of RAS genes were classical oncogenic mutations in 
KRAS and NRAS affecting codons 12, 13, 61 or 146 (Fig. 1B,C). In two cases semi-classical mutations were identified. 
In one case p.Q22K was observed in KRAS. This mutation is rarely found in tumour samples and shown to display 
increased GTP loading18. Another case harboured an in frame deletion-insertion, simultaneously affecting codons 12 
and 13 of KRAS, resulting in p.G12A and p.G13H. This specific variant was, to the best of our knowledge, not described 
previously. However, both mutations effect classical positions in the P-loop. It is likely that this variant display increased 
GTP loading. The remaining 6 cases contained an in-frame insertion in HRAS or KRAS resulting in the insertion of 7 
to 10 residues around position 65 (Figs 1B,C and 2A, Supplementary Information). These cases represented 2.0% of all 
cases and 40% of cases with RAS variants (Fig. 1A,B).
Sequence analysis of HRAS, KRAS and NRAS with an identical approach in 3234 oncology diagnostic requests, 
resulted in the identification of 354 variants of KRAS and 21 variants of HRAS. The observed mutational spectrum 
is in line with the literature19 and did not reveal any insertion or duplication variants around position 65 (Fig. 1C). 
This suggests that the RAS in-frame insertion variants are disease-specific. Therefore, the 6 in-frame insertion 
variants detected in VMOS will be referred to as VMOS RAS variants.
Clinical Characteristics of VMos RAs variants. All patients with in-frame insertion variants of KRAS 
and HRAS were (young) adults (Supplementary Information). All patients except one were male and had rela-
tively large (5 to 10 cm) progressive and usually painful swellings of arm, leg, abdominal wall, back musculature 
or face. Clinically, the swellings appeared as vascular or lipoma-like. Radiological investigation by ultrasound or 
MRI showed vascular characteristics, sometimes with high flow, but without the characteristics of arteriovenous 
malformation (AVM) at angiography (case 3).
In silico analysis of VMOS RAS variants. On amino acid level the DNA duplications and insertions found 
in the VMOS RAS variants resulted in an insertion of mainly duplicated sequence around position 65 (Fig. 2A). 
It is difficult to predict to what extent the insertions interfere with the overall protein fold. A general destabili-
sation would cause reduced nucleotide affinity and thus probably increased GTP loading. It is possible that the 
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disturbances of the insertions are largely absorbed by the loop connecting β-sheet 3 and helix α2 (Fig. 2B). This 
loop constitutes a major component of the interaction surface with GEFs and thus strong impact on GEF interac-
tion is expected (Fig. 2C). The insertions likely affect in particular the C-terminal part of the loop. The N-terminal 
part of the loop interacts with GAPs and contains Gln61, a residue involved in GTP hydrolysis (Fig. 2D). The 
insertions are not necessarily expected to be incompatible with GAP interaction, but impact on it is likely. The 
loop is spatially rather distant to the binding sites of RAS Association (RA) domains and RAS Binding Domains 
(RBDs) (Fig. 2E). These domains are found in RAS effectors, adapt ubiquitin folds, and interact with RAS•GTP in 
a similar manner20. The RasGEF SOS contains besides the catalytic site an allosteric site that binds to RAS•GTP 
(Fig. 2E). Binding of RAS to the allosteric site increases the catalytic activity of SOS resulting in a positive feed-
back21,22. The allosteric site in SOS is not constituted by an ubiquitin fold, but interacts with similar region as RAS 
effector proteins with an ubiquitin fold (Fig. 2E).
The clinical context indicated that VMOS RAS variants cause enhanced RAS signalling, but the outcome of 
the in silico analysis is not unambiguously supporting this expectation. In fact, it strongly suggested deficiencies 
in GEF catalysed nucleotide exchange, which would result in reduced signalling. An exact judgement of the 
functional consequences of the insertions thus requires experimental analysis. As the insertion observed in case 5 
Figure 1. Identification of RAS in-frame insertion variants. (A) Pie-chart showing potentially causative 
variants found in 299 diagnostic cases with VMOS. RAS: HRAS, KRAS or NRAS; others genes from panel, 
variation in one of the sequenced genes with exception of RAS genes; no gene from panel, no variation in any 
sequenced gene (details in Materials and Methods). (B) Pie-chart of the type of RAS variants found. White, 
classical mutations; grey in-frame insertions around amino acid position 65. K, KRAS; N, NRAS. Mutation 
on amino acid level. (C) Comparison of the RAS variants found in cases of VMOS with variants identified 
in 3234 oncology related diagnostic requests. Each box represents one codon. Grey boxes, codons covered 
by NGS analysis. The variants found in oncology related diagnostics and VMOS cases are indicated above and 
underneath of the affected codons, respectively. Each circle/item represents one case.
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co-occured with p.Q61L, a classic pathogenic missense mutation, the following analysis is focused on the other 
VMOS RAS variants. The impact of the insertion on nucleotide exchange, effector binding, and GTP hydrolysis 
was systematically checked.
Figure 2. Structural context of VMOS RAS insertions. (A) Sequence alignment on amino acid level from 
position 50 to 80. The sequences of HRAS and KRAS are identical in the aligned region and labelled as wild 
type. Duplicated sequence is highlighted once by light red and once by yellow background; novel sequence 
by light blue and point mutations by red background. Note: This colour coding is irrespective of the genetic 
rearrangements on DNA level purely based on the amino acid sequence. Elements of secondary structure are 
displayed above the alignment, with helix α2 in dark blue and N- and C-terminal connecting loops in light 
blue. The position of Q61 is marked by a red circle. The affected genes are indicated left to the alignment. Case 
number, Variant Allele Frequency (VAF), and age and sex of the patient are listed right to the alignment. (B) 
Structure of HRAS in complex with the hydrolysis resistant GTP analogue GppNHp in ribbon representation 
but with helix α2 and its connecting loops as dark blue backbone trace. Cα-atoms in the backbone trace are 
shown as colour coded spheres: helix α2, dark blue; connecting loops, light blue; Gln61, red. This region 
corresponds to switch II. Switch I is highlighted in magenta. Style of representation and colour code is 
maintained throughout this figure. The likely place of insertion is indicate by an arrow. Dark grey, GppNHp in 
ball-and-stick representation. (C–E) Structures of HRAS (ribbon representation, dark grey) in complex with 
SOS acting as GEF (C), RasGAP (D), and the effectors RalGDS (E, left), PI3K (E, middle) and SOS (E, right) 
(space filling representation). Nucleotides are shown in ball-and-stick representation in black: GDP•AlF3 (D) 
and GppNHp (E). The ubiquitin folds of RalGDS and PI3K mediating the interaction with RAS are coloured 
in orange. See Supplementary Fig. 1B for RAS in complex with the ubiquitin folds of the effectors RAF38, 
PLCε39, and Nore140. Note: The orientation of RAS is different in each panel, but identical for all complexes in 
(E) to allow for a free view of the interaction surface. See Supplementary Fig. 1A for a set of figures in identical 
orientation. Figures were generated base on the pdb database entries 5p2115, 1dbk32, 1wq116, 1lfd41, 1he842, and 
1nvv22 by use of the programs molscript43 and raster3D44.
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Nucleotide exchange. To analyse nucleotide exchange, recombinant RAS was loaded with the fluorescent 
GDP analogue mGDP and nucleotide exchange was monitored in the presence of excess GDP as a decay of 
fluorescence intensity. The intrinsic dissociation rate from wild type RAS and VMOS RAS variants are indistin-
guishable (Fig. 3A–G). This suggested that the nucleotide affinity of the VMOS RAS variants is not altered. Unlike 
the classical codon 117 or 146 missense mutations, pathogenicity of the VMOS RAS variants does therefore not 
originate from increased GTP loading due to reduced nucleotide affinity and fast nucleotide exchange.
The GEFs SOS and RasGRP1 catalyse nucleotide exchange of wild type HRAS and KRAS (Fig. 3A,E). 
However, the exchange rates of the VMOS RAS variants remain unchanged in the presence of GEFs (Fig. 3B–
D,F). To demonstrate proper nucleotide loading of the VMOS RAS variants, EDTA was added in a control reac-
tion. One Mg2+ ion is bound to small G-proteins and co-ordinated in part by the negative charged oxygens from 
the phosphate moiety of the nucleotide. Upon complexation of Mg2+ by EDTA, the nucleotide affinity of the small 
G-proteins is drastically reduced, resulting in fast nucleotide dissociation. Indeed, all RAS variants were initially 
loaded with mGDP properly.
Even though SOS and RasGRP1 were unable to catalyse nucleotide exchange of the VMOS RAS variants, it is 
formally not excluded that a ternary complex between the GEF and the nucleotide loaded G-protein is formed. In 
such a scenario, the VMOS RAS variant could act as dominant negative by sequestering GEFs in an unproductive 
complex. To exclude this possibility, RasGRP1 mediated nucleotide exchange of KRAS•mGDP was measured in 
the presence of an up to 100 fold higher concentration of the case 1 KRAS variant (Fig. 3G). Indeed, the presence 
of the variant did not reduce the rate of RasGRP1 mediated nucleotide exchange of KRAS wild type.
When the same experimental set-up was used with SOS, a strong enhancement of SOS mediated nucleotide 
exchange of KRAS•mGDP was measured in the presence of KRAS and HRAS variants (Fig. 3H,I). This indicates 
that the variants were still able to activate SOS by binding to the allosteric site. It is for technical reasons not 
possible to compare the variants with wild type RAS, as wild type RAS would compete with KRAS•mGDP for 
the catalytic site. The case 2 HRAS variant seemed to be less potent in activating SOS if compared to the other 
variants, which could be explained by a reduced affinity for the allosteric site. In summary, as predicted by the 
in silico analysis, nucleotide exchange by GEFs was perturbed, but the variants were still able to activate SOS by 
binding to the allosteric site.
Effector interaction. The interaction of G-protein and the nucleotide is stabilised in the ternary complex 
with the effector and in consequence the rate of nucleotide dissociation is reduced. This effect was used to ana-
lyse the interaction of wild type and VMOS RAS variants with the RAS Binding Domain of RAF (Raf-RBD) 
(Fig. 4A,B). RAS was loaded with the hydrolysis resistant fluorescent GTP analogue mGppNHp and the nucleo-
tide dissociation rate was determined in the presence of excess GppNHp and various concentrations of Raf-RBD. 
Both HRAS and KRAS interacted with Raf-RBD with a Kd of 0.2 μM. The affinities for the interaction of case 1 
and case 3 variants were very similar to the respective wildtype protein (Fig. 4A–C). The affinities of the case 2 and 
case 4 variants were increased, but as the titrations were performed at a concentration of 0.2 μM of the G-protein 
Kd values much lower than 0.2 μM could not be determined accurately. For comparison, KRAS p.G12V was 
included as a classical oncogenic variant. KRAS p.G12V interacted with a similar affinity with Raf-RBD as wild 
type KRAS (Fig. 4B,C). However, the intrinsic dissociation rate of mGppNHp was increased by a factor of about 
3 compared to wild type and the VMOS RAS variants (Fig. 4B).
To confirm that the isolated RAS binding domain reflected the interaction of full length RAS effectors, wild 
type and VMOS RAS variants were loaded with the hydrolysis resistant GTP analogues GTPγS, immobilised, and 
used to precipitate proteins from HeLa cell extracts. The RAS effector proteins ARAF, BRAF, RAF1, RGL1, RGL2, 
RGL3 and RIN1 were identified in the precipitates obtained with wild type and all VMOS RAS variants but not 
with several unrelated control proteins (Fig. 4D), showing that at least in case of the identified proteins interaction 
with the full length effector was possible.
GTP-hydrolysis. GTP hydrolysis was followed over time by terminating the reactions at different points in 
time, and GDP and GTP contents analysis by HPLC. The intrinsic GTP hydrolysis rates of VMOS RAS variants 
were reduced by a factor 10 relative to wild type (Fig. 5A–C). The same extent in reduction of the intrinsic hydrol-
ysis rate was observed for the classical oncogenic KRAS p.G12V variant (Fig. 5B,C). The differences between 
wild type and mutated RAS were also reflected by the different GTP content at time zero, as GTP hydrolysis had 
already occurred during the procedure of nucleotide loading and further preparations of the proteins (Fig. 5A,B).
To analyse the effect of the VMOS RAS variants on GAP catalysed GTP hydrolysis, G-proteins were incubated 
in the presence of various concentration of RAS-GAP. GTP and GDP content was analysed after termination 
of the reaction after 70 minutes (Fig. 5D,E). In case of the wild type proteins, an additional series was recorded 
with termination after 20 minutes (Fig. 5D,E). The classical oncogenic variant KRAS p.G12V was taken along for 
comparison (Fig. 5E). RAS-GAP was still able to stimulate GTP hydrolysis of all analysed VMOS RAS variants, 
though stimulation seemed to be less efficient than with wild type HRAS and KRAS. The VMOS RAS variants 
were clearly distinct from KRAS p.G12V, as RAS-GAP was not able to stimulate GTP hydrolysis of KRAS p.G12V 
even at the highest concentration used (Fig. 5E).
Furthermore, KRAS wild type and the case 1 KRAS variant were subjected to a more detailed analysis 
for which GTP hydrolysis was monitored over time in the presence of various concentrations of RAS-GAP 
(Fig. 5E,G). While 0.25 μM of RAS-GAP enhanced the GTPase activity of KRAS wild type by a factor of about 
3.5, no effect was observed on the case 1 variant. Enhancing effects with the case 1 variant were observed at 
2.5 μM and 25 μM. At these concentrations GTP hydrolysis of KRAS wild type became too fast to be resolved. 
The dependency of GTP hydrolysis of the RAS-GAP concentration thus suggested that the affinity of the VMOS 
variants for GAPs was reduced.
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Figure 3. VMOS RAS variants are insensitive to GEFs. (A–F) Nucleotide exchange rates in the absence or 
presence of RasGRP1 (150 nM) or SOS (1.5 μM) of wild type (A,E) and variant RAS (B–D,F). For variant RAS 
an additional control was included to which EDTA was added at the indicated point in time. (G) RasGRP1 
(150 nM) catalysed nucleotide exchange activity on wild type KRAS (200 nM) in the presence of various 
concentrations of the KRAS case1 variant. (H) SOS (150 nM) catalysed nucleotide exchange activity on wild 
type KRAS (200 nM) in the presence of variant RAS (20 μM) as indicated. Variant RAS was used as obtained 
from the protein purification and therefore in part loaded with GDP and in part with GTP. The portion of GTP 
loaded RAS was 64% (case 1), 71% (case 2), 39% (case 1), and 77% (case 4). Note: The reduced ability of the 
case 2 variant cannot be attributed to lower GTP loading. (I) SOS catalysed nucleotide exchange was measured 
as in (H) in the presence of various concentration of the case 1 KRAS variant. The decay of the fluorescence 
signal was fitted to a single exponential functions and the obtained rate constants (kobs) were plotted against the 
concentration of the KRAS variant.
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Functional characterisation of VMos RAs variants. The biophysical characterisation of the VMOS 
RAS variants showed two opposing effects. VMOS RAS variants appeared insensitive to the action of GEFs with a 
consequently decrease of signalling capability. On the other hand, VMOS RAS variants showed reduced intrinsic 
and GAP catalysed GTP hydrolysis with an increase of signalling capability as consequence. To analyse the net 
consequences of these opposing effects in the cellular context, A14 cells were transiently transfected with either 
HA-tagged versions of HRAS, HRAS p.G12V or VMOS variants of HRAS (Figs 6 and S1). Cell lysates were ana-
lysed for the level of phosphorylated ERK (pERK) to monitor RAS induced RAF activity. pERK levels were found 
to be low in empty vector controls and slightly increased in cells transfected with wild type HRAS. HRAS p.G12V 
and the VMOS RAS variants caused a clear induction of pERK levels (Fig. 6A,B and Supplementary Fig. 2). 
Furthermore, cell lysates were analysed for phosphorylated AKT (pAKT) at Ser473 to monitor RAS induced PI3K 
activity. Whereas HRAS p.G12V and the case 3 variant induced phosphorylation of AKT no enhancement was 
observed with the case 2 and case 4 variant (Fig. 6A,C).
Meta-analysis of comparable in-frame insertions in RAS genes. An in-house database search for 
insertions comparable to the VMOS RAS variants revealed one in-frame insertion in KRAS in a case suspected 
for Noonan syndrome (Fig. 7A). Furthermore, a screen of the current literature and public databases COSMIC 
and ClinVar identified a total of 7 different insertions in 10 cases (Fig. 7A). One insertion is reported for two 
independent cases of Costello syndrome23,24 and 6 different insertions are reported for 8 tumour samples25–30. 
Though these variants are similar to the VMOS RAS variants, it is possible that they have acquired a stronger 
signalling capability. For example, it seems that at least some of the insertions found in tumours extended more to 
the N-terminal side compared to the VMOS RAS variants. In consequence, the impact of these insertions on the 
catalytic Gln61 might be stronger. To test this, RasGAP catalysed GTP hydrolysis was monitored with the KRAS 
variant found in Noonan and three selected variants described in tumours (Fig. 7B). All four variants displayed 
a very similar behaviour as VMOS RAS variants, excluding the possibility that the variants found in tumours 
enhance signalling stronger than the VMOS RAS variants.
Discussion
From a cohort of 299 samples of VMOS, 15 cases with variants in either HRAS, KRAS or NRAS were identified. 
While in nine of these a classical or semi-classical pathogenic missense variant was present, six cases harboured 
an insertion of 7 to 10 amino acid residues around position 65 (Fig. 1). Thus classic pathogenic variants and 
this type of insertion variants were found at a ratio of 2:1. An extensive literature search and a search of the 
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COSMIC database identified in total ten reported cases with similar insertions in either HRAS, KRAS or NRAS 
(Fig. 7A). One insertion was found in two independently reported patients with Costello syndrome23,24. The 
remaining eight reported variants including in total six different insertions were detected in tumour samples. The 
low number of reported similar insertions is surprising as RAS genes are extensively sequenced in tumour speci-
mens. In part, this might be explained by the difficulties in alignment and variant detection of such insertions in 
NGS-based analysis and the focus on hotspot locations in the RAS genes that do not extend towards the positions 
around amino acid 65. However, also in our routine diagnostics for oncology requests, no such insertion variants 
were identified (Fig. 1). Therefore it is possible that the relative frequencies of RAS variants detected in different 
diseases reflect the extent of mutational activation.
The biophysical characterisation performed here suggested that these type of insertion variants are weakly but 
constitutively activating. The GEFs SOS and RasGRP1 did not display any activity to the variants. It is expected 
that this holds true for other known RasGEFs as well, since these GEFs are structurally related31. The crystal 
structure of the RAS•SOS complex demonstrates that the region between residue 60 and 70 of RAS is involved 
in extensive interactions with SOS32, strongly suggesting that insertions in this region are not tolerated by GEFs. 
Furthermore, point mutations in this region impact on the selectivity of the interaction between GEF and 
G-protein33. The RAS in-frame insertion variants thus seemed to be decoupled from activating cellular signals 
via the regulation of GEFs. Opposite to RAS proteins mutated at position 12 or 13, the RAS in-frame insertion 
variants were solely dependent on intrinsic nucleotide exchange that did not differ from wild type. Any increase 
Figure 5. VMOS RAS variants displayed reduced GTPase activity. (A,B) The GTP fraction p(GTP) of the 
total nucleotide load of wild type and mutated HRAS (A) and KRAS (B) was followed over time. The time 
dependent decay of p(GTP) was fitted as single exponential decay (solid line) to determine the rate of intrinsic 
GTP hydrolysis kintrinsic. (C) Intrinsic GTP hydrolysis rates kintrinsic as determined in (A,B). (D,E) RasGAP 
catalysed GTPase activity of wild type and variant HRAS (D) and KRAS (E). p(GTP) was determined at time 
zero and after τ = 70 minutes of incubation in the presence of various concentration of RasGAP. Wild type RAS 
was in addition analysed after τ = 20 minutes. Solid lines connect the data points belonging to the series of a 
RAS variant. (F,G) Time dependent GTP hydrolysis of KRAS wt (F) and KRAS (G) in the presence of various 
RasGAP concentration. The dependent decay of p(GTP) was fitted as single exponential decay (solid line) 
to obtain kobs. Note: Different scales are used in (F,G). (H) kobs as obtained in (F,G) were plotted against the 
concentration of RasGAP. Solid lines connect the data point belonging to one series.
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in the GTP loaded fraction of the RAS in-frame insertion variants therefore has to be a consequence of impaired 
GTP hydrolysis. The intrinsic GTPase activity of the insertion variants was reduced by a factor 10. This is com-
parable to the p.G12V variant. RasGAP catalysed GTP hydrolysis was impaired but not abolished in the RAS 
in-frame insertion variants, whereas this was the case for p.G12V variants. Overall the RAS in-frame insertion 
variants are less likely to undergo transition from the GDP bound state to the GTP bound state than wild type 
RAS or RAS mutated at position 12 or 13. Transition from the GTP bound state to the GDP bound state occurs 
less likely in RAS in-frame insertion variants than in wild type but more likely in RAS mutated at position 12 and 
13. The experiments in A14 cells would be in agreement with a shift of the net balance between the GDP and the 
GTP bound state to the GTP bound state in the RAS in-frame insertion variants.
Overall, VMOS variants seemed able to interact with effector proteins, though the interaction may be atten-
uated to different degrees for the individual VMOS variants. The case 2 and case 4 variants displayed increased 
affinity for the isolated Ras Binding Domain of RAF (Fig. 4A–C). On the other hand, the case 2 variant seemed 
to be less efficient in enhancing SOS activity by binding to the allosteric site of SOS (Fig. 3H) and the case 2 and 
the case 4 variants did result in phosphorylation of ERK but not AKT if transfected in A14 cells (Fig. 6). The 
divergence of these effects may in part be explained by the steric demand of the insertions. Based on the availa-
ble structural information it is expected that the insertions do not perturb the core effector interaction surface 
in RAS. However, clashes may occur with effector-specific parts in close proximity to the binding site (Fig. 2E).
The clinical manifestation of RAS variants is influenced by additional parameters. The type of the affected 
cell and the origin of the variant, germline or somatic, are obvious important factors. Of speculative nature is the 
influence of biochemical different behaviours of variants. For example, cells might react differently to the RAS 
in-frame insertion variants with a constitutive basal increase of RAS•GTP levels than to p.G12 variants where in 
addition RAS•GTP levels overshoot in response to GEF activation.
The strongly activating effect of RAS proteins mutated at positon 12 or 13 typically results in enhanced cell 
growth and drives the formation of tumours. These variants do not commonly occur in the germline and if so, 
Figure 6. VMOS RAS variants enhance RAS signalling in vivo. (A) A14 cells were transfected with HA-tagged 
versions of wild type and mutated versions of HRAS as indicated. Cell lysates were subjected to SDS-page 
and Western blotting. Blots were probed with α-HA, α-ERK, α-pERK, and α-pAKT. Per experiment each 
transfection condition was duplicated (same transfection mix spilt of two dishes of cells). This figure shows one 
representative experiment and four independent experiments are shown in Supplementary Fig. 2. Full scans of 
the blots shown in this figure are provided as Supplementary Fig. 3. (B,C) Quantification of the levels of pERK 
(B) and pAKT (C) obtained in all five experiments. The intensity of the bands were integrated and background 
subtracted. Bar graphs with the intensity values obtained for the individual bands are shown in Supplementary 
Fig. 2. For each experiment the intensities of the duplicated transfections were averaged and normalised to the 
empty vector control resulting in five values per condition. Here, the average of these values and their standard 
deviation are shown as bar graphs.
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phenotypes are severe. From six published RAS in-frame insertion variants in tumours literature variants #2, #3 
and #4 were tested here for GTPase activity (Fig. 7A). All three tested variants displayed very similar deficiencies 
regarding GTP hydrolysis as VMOS RAS variants (Fig. 7B). In agreement with this, enhanced RAS signalling 
was reported in cell lines upon expression of the literature variants #1, #2, and #323,25. It is not proven, that these 
variants indeed act as drivers of tumorigenesis. However, it seems most plausible that the risk of tumour forma-
tion increases with the extent to which RAS signalling is enhanced. But even strongly enhancing variants do not 
automatically cause cancer. This was reflected by the relative low number of classical RAS variants in the cohort of 
299 VMOS cases, compared to cases of tumour diagnostics. On the other hand, weakly enhancing RAS variants 
of the VMOS type only rarely manifest themselves in tumours and are thus found with much higher frequencies 
in clinical manifestations of mild enhanced tissue growth.
In conclusion, we have characterised a novel type of insertions in RAS genes that weakly enhance consti-
tutive signalling. All analysed variants were unresponsive to GEFs and displayed reduced intrinsic and GAP 
catalysed GTPase activity. These variants were likely causative in about 2% of the patients with atypical VMOS 
analysed here. It remains speculative whether and with which frequency these variants also occur in more com-
mon cases of VMOS, which usually do not require tissue examination and are thus not subjected to NGS as 
standard. However, newly identified pathogenic variants in atypical VMOS are of particular clinical interest, as 
diagnosis and treatment of atypical cases may be very challenging. Similar variants are found in incidental cases 
of RASopathies. Thus, this work adds a new class of RAS variants to the clinical spectrum that should be included 
in diagnostic sequencing.
Material and Methods
Patient cohort and next generation sequencing. In the period from January 2016 to June 2018, a total 
of 299 samples with clinical, histological or radiological evidence of VMOS were successfully screened. Study pro-
tocols on the clinical, histological and molecular data was performed with approval of the medical ethical board 
of the Radboudumc, Nijmegen, the Netherlands (number 2016–2310). Human tissue samples were obtained 
with oral informed consent for routine diagnostic analysis, which includes sequence analysis of affected tissue 
to detect acquired mutations. The need of written consent was waved by the ethical board as incidental findings 
were not expected. The identified acquired RAS variants were subject to further investigation through in vitro 
experiments using unrelated cell lines. No human tissue samples were used for experimental purposes. DNA iso-
lation and library preparation were performed as previously described34. Libraries for sequencing on the NextSeq 
500 (Illumina) were generated using Single Molecule Molecular Inversion Probes (smMIPs). This method uses 
unique molecule identifiers to allow consensus based error correction and the deduction of the actual number of 
sequenced gDNA molecules. This allows both sensitive detection of variants down to 1% variant allele frequency 
and specification of the sensitivity of sequencing on a case by case basis For the RAS genes, the analysis focused on 
Figure 7. GAP catalysed GTPase activity of VMOS related RAS variants. (A) Sequence alignment as in 
Fig. 2A of a KRAS variant found in a Noonan patient (case 7; this study), a HRAS variant found in two patients 
with Costello (lit 1;23,24) and of 6 variants of either KRAS or NRAS found in 8 different tumour samples (lit 
2–7;25–30). The number of independent observations of the variant and the context is indicated on the right of 
the alignment. Colour coding as in Fig. 2A. (B) p(GTP) was determined at time zero and after 70 minutes of 
incubation in the presence of various concentration of RasGAP as in Fig. 5.
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hotspots and surrounding sequences of HRAS (NM_005343.2): codon 12, 13, 59 and 61, KRAS (NM_004985.4): 
codon 12, 13, 59, 61, 117 and 146 and NRAS (NM_002524.4): codon 12, 13, 59, 61, 117 and 146.
For 224 cases, the panel consisted of a cancer hotspot panel targeting the following hotspots and surrounding 
sequences in the following genes: AKT1, BRAF, CTNNB1, EGFR, ERBB2, GNA11, GNAQ, GNAS, H3F3A, H3F3B, 
HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MLP, MYD, NRAS, PIK3CA, PDGFRA. For 75 cases, analysis was per-
formed with a dedicated VMOS panel targeting hotspots and surrounding sequencing in the genes AKT1, AKT2, 
ATK3, BRAF, GNA11, GNA14, GNAQ, GNAS, HRAS, IDH1 IDH2, KRAS, MTOR, NRAS, PIK3CA, PIK3R2 and 
TEK and >90% of coding and splice sequences of PTEN and RASA1.
Purification of recombinant protein. HRAS (aa 1–166, Homo sapiens) was expressed from the ptac plas-
mid in the bacterial strain CK600K and purified as described35. KRAS (aa 1–170, Homo sapiens) was expressed 
as GST-fusion proteins from pGEX6P3 and the GST-tag was removed by cleavage with PreScission Protease as 
essentially as described36. HRAS and KRAS mutants were generated by QuikChange mutagenesis and purified 
as the wild type proteins. SOS1 (aa 564–1049, Homo sapiens) and RasGRP1 (aa 1–461, Rattus norvegicus) were 
expressed as HIS-tagged proteins using the pET vector system as described33. RasGAP (aa 722–1056, Homo 
sapiens) were expressed as GST-tagged proteins from the pGEX6P3. Protein production in CK600K bacteria 
was induced by 100 nM IPTG (isopropyl β-D-1-thiogalactopyranoside) at 25 °C. After 20 hrs, the bacteria were 
collected by centrifugation, resuspended in buffer A (50 mM TrisHCl pH 7.5, 50 mM NaCl, 5% glycerol and 
5 mM β-mercaptoethanol) supplemented with 100 μM PMSF and lysed by sonication. The lysate was cleared by 
centrifugation and applied to glutathione agarose column equilibrated in buffer A. The column was washed with 
10 to 15 volumes of buffer B (50 mM TrisHCl pH 7.5, 400 mM NaCl, 5% glycerol and 5 mM β-mercaptoethanol), 5 
volumes of buffer A and eluted with 20 mM glutathione in buffer A. The protein containing fractions were pooled 
and concentrated. Cleavage of the GST tag was performed by the addition of PreScission Protease was added 
with a ration 1:500 (g protease/g protein) at 4 °C overnight. RasGAP was further purified by gel-filtration on a 
Superdex 75 26/60 column (GE-Healthcare) equilibrated with buffer C (50 mM TrisHCl pH 7.5, 400 mM NaCl, 
and 5 mM β-mercaptoethanol). RasGAP containing fractions were polled concentrated and remaining GST was 
removed by passing the protein over a glutathione agarose column.
GEF mediated nucleotide exchange. GEF mediated nucleotide exchange was determined as described 
previously33. Briefly, reaction were performed with 200 nM of G-protein•mGDP in the presence of 20 μM GDP 
in buffer containing 50 mM TrisHCl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 5% glycerol, and 5 mM DTT at 20 °C. 
RasGRP1 was used at 150 nM, Sos at 1500 nM or 150 nM, and EDTA at 10 mM.
G-protein effector interaction. G-proteins were loaded with the hydrolysis resistant fluorescent GTP 
analogue mGppNHp33. 200 nM G-protein•mGppNHp were incubated in the presence of 20 μM GppNHp and 
various concentrations of the RBD of Raf at 35 °C in buffer containing 50 mM Tris HCl, ph 7.5, 50 mM NaCl, 
5 mM MgCl2, 5 mM DTT and 5% glycerol. Fluorescence intensity was monitored over time and the fluorescence 
traces fitted as single exponential decay with offset to obtain the rate constant kobs. kobs were plotted against the 
concentration of Raf-RBD and affinities were determined by data fitting as described35.
Mass spectroscopy. After clean up peptides obtained from the trypsin digested precipitates were separated 
on a 30-cm pico-tip column (50 μm ID, New Objective) packed with 3 μm aquapur gold C-18 material (Dr. 
Maisch) by applying a gradient (7–80% ACN 0.1% FA, 140 min), delivered by an easy-nLC 1000 system (LC120, 
Thermo Scientific), and electro-sprayed directly into an LTQ Orbitrap Mass Spectrometer (Velos, Thermo 
Scientific). Raw files were analysed with the MaxQuant software version 1.5.1.0. with oxidation of methionine set 
as variable and carbamidomethylation of cysteine as fixed modification. The Human protein database of UniProt 
was searched with peptide and protein false discovery rate set to 1%.
GTPase activity. G-proteins were loaded with GTP as described33. G-proteins were incubated at a concentra-
tion of 250 μM in buffer containing 50 mM TriHCl, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 5 mM β-mercaptoethanol 
and 2.5% glycerol at 25 °C in 5 μl aliquots. The reaction was terminated by the addition of 100 μl acetonitrile at 
various points in time and immediately flash frozen in liquid nitrogen. The samples were concentrated to dryness 
in at reduced pressure and re-suspended in 100 μl water. To remove protein 10 μl of a suspension containing 50% 
OligoR3 C18 material in methanol were added. After 20 minutes incubation samples were filtered through a frit-
ted 96 well plate (Nalgene), concentrated to dryness under reduced pressure and re-suspended in 30 μl water. 20 μl 
of sample were injected for analysis by HPLC (Ultimate 3000, Thermo Scientific) and nucleotides separated on 
a C18_A0.3 μm 150 × 4.6 mm column (Dr. Maisch) with 0.5 ml/min isocratic flow of buffer containing 100 mM 
KPO4 pH 6.5, 10 mM Terabutylammoniumbromide and 10% acetonitrile and absorbance was detected at a wave-
length of 260 nm. The identity of peaks were confirm by GDP and GTP standards. Peaks were integrated and 
p(GTP) was determined as peak integral GTP/(peak integral GTP + peak integral GDP).
ERK-activation and Western blotting. A14 cells37 were cultured in 6 polystyrene well plates (Corning) 
in DMEM high glucose medium (Lonza) supplemented with 10% fetal bovine serum (Bodinco BV), 100 U/l 
penicillin streptomycin mixture (Lonza), and 20 mM L-glutamine. Cells were transfected with pMT2-HA vector 
or vector containing the indicated RAS variants with extreme gene (Roche) following the manufactures instruc-
tions. Two days after transfection and growth in full medium cells were harvested by scraping into 1X SDS sample 
puffer. Cell lysates were subjected to SDS page and blotted to PVDF membrane. Expression of RAS variants was 
monitored via the HA-tagged with a homemade monoclonal mouse anti-HA antibody (12CA3). Phosphorylated 
ERK was monitored with monoclonal rabbit antibody P-p44/42 MAPK (Cell Signalling 4370), total ERK with 
a homemade polyclonal rabbit antibody (6D3), and phosphorylated AKT with the monoclonal rabbit antibody 
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pAKT S473 D9E (Cell Signalling 4060). For detection fluorescently labelled secondary anti mouse or anti rabbi 
antibodies were used (Alexa Fluor 680 and Alexa Fluor 800, Thermo Fisher Scientific GE). Fluorescence was read 
with a Typhoon scanner (Amersham GE) with a pixel size of 10 μm × 10 μm (corresponding to 2540 dpi) and a 
detection range of 16 bit. In figures the information containing range is visualised in an 8 bit gradient of grey scale. 
None orthogonal transformations and scaling in figure preparation was kept to a minimum.
ethical statement. The Study was performed with approval of the medical ethical board of the 
Radboudumc, Nijmegen, the Netherlands (number 2016–2310) and was in accordance with the Code of Conduct 
of the Federation of Medical Scientific Societies in the Netherlands. Oral informed consent was obtained from 
all patients.
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